Pharmacyclics Inc

Pharmacyclics — Technical Presentation (December 2012)

24 slides from Pharmacyclics's technical presentation, Dec 11, 2012

  1. Slide 1: Disclosures

    Disclosures MICHAEL Wanc, MD » RESEARCH FUNDING: Pharmacyclics, Janssen, Celgene, Millennium, Novartis, Onyx, Cellular Therapeutics + EMPLOYEE: None » STOCKHOLDER: None » CONSULTANT: None » Honorarium: Onyx, Millennium, Celgene * SCIENTIFIC ADVISORY BOARD: Pharmacyclics, Janssen

  2. Slide 2: Interim Results of Phase 2 Study of Ibrutinib in Relapsed or Refractory MCL

    Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability With Longer Follow-up Michael Wang, MD", Simon Rule, MD, Peter Martin, MD°, Andr

  3. Slide 3: Bruton's Tyrosine Kinase (BTK): A Critical Kinase for Lymphoma Cell Survival and Proliferation

    Bruton’s Tyrosine Kinase (BTK): A Critical Kinase for Lymphoma Cell Survival and Proliferation B cell receptor * Bruton’s tyrosine kinase (BTK) is an essential element of the BCR signaling pathway (Niro, NRI 2002) + Inhibitors of BTK block BCR signaling and induce apoptosis + PCI-32765 (Ibrutinib) f

  4. Slide 4: Study Design: PCYC-1104-CA

    Study Design: PCYC-1104-CA International, multicenter, open-label, phase II single-agent study of ibrutinib in 2 patient populations with relapsed or refractory MCL Treatment: 560 mg orally daily until progression (Cycle = 28 days) Objectives: — Overall response rate (ORR), duration of response (DOR

  5. Slide 5: Results

    Results - Conducted at 18 sites (9 U.S. and 9 E.U.) Data cut on Sept 21, 2012 Patient population (ITT) n = 115 — Enrolled from Feb. 15, 2011 to Mar. 21, 2012 Safety population (21 dose of ibrutinib) = 111 patients Efficacy population = 110 patients — Evaluable for response — At least one post-baseli

  6. Slide 6: Patient Eligibility

    Patient Eligibility » Confirmed MCL, with cyclin D1+, or t(11;14), and measurable disease - Failure to achieve at least partial response (PR) to, or disease progression after, most recent treatment regimen - Atleast 1, but not > 5 prior lines of therapy for MCL » Adequate end-organ function — ANC 20

  7. Slide 7: Patient Characteristics

    Patient Characteristics Bortezomib-Naive Bortezomib-Exposed Total (N=65) (N=50) (N=115) hee °° ee ||| ener Male 48 (74%) 41 (82%) aoe (77%) 55 (85%) 9 (14%) 1 (1%) %) Prior a Median (Range) 2 (1-6) 3 (1-5) 3 (1-6) 23 regimens 29 (45%) 32 (64%) 61 (53%) Median Months Since 29 (3-214) 48 (7-224) 42 (3

  8. Slide 8: Disease History

    Disease History Bortezomib-Naive Bortezomib- Total (N=65) Exposed (N=50) (N=115) EPHOERIgR ROR OBE HES i Hyper CVAD 18 (28%) 15 (30%) 33 (29%) Stem cell transplant 7 (11%) 4 (8%) 11 (10%) Prior Lenalidomide 8 (12%) 19 (38%) 27 (23%) ai atew suse Intermediate risk 23 (35%) 18 (36%) 41 (36%) High risk

  9. Slide 9: Treatment Related and Unrelated AEs Occurring in >10% of Patients

    Treatment Related and Unrelated AEs Occurring in >10% of Patients (1014 cycles administered to all pts) Hematogenous AE: Neuropent ‘Tontonopena rena Non-Hematogenous AE: Fang Upper eptatr tract dion ysonoea ‘cetera perenera

  10. Slide 10: Treatment Related and Unrelated Infection AEs

    Treatment Related and Unrelated Infection AEs Grade 3 or Above (1014 cycles administered to all pts) Pneumonia Cellulitis Sepsis Urinary tract infection Bacteraemia Citrobacter infection CClostriial infection Herpes zoster ophthalmic =] Grace 7 Infection ra Klebsiella infection Ml Grade 5, Lower res

  11. Slide 11: Treatment Related and Unrelated Hemorrhagic AEs

    Treatment Related and Unrelated Hemorrhagic AEs All Grades in 22% of Patients (1014 cycles administered to all pts) Contusion Episanis mate! Petechiae Grade 2 Ecchymosis Grade 3 Haematuia Grade 4 Subdural haematoma Mi Grade 5 Purpura 0% © 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% All 4 subdural hemat

  12. Slide 12: Best Response

    Best Response (Efficacy Population n=110, Median Follow-up 9.2 mo) =CR &PR 100 = 8 , 72% 68% =! 65% r= & 60 a i} ¢ 40 5 2 5 a 20 21% 23% 22% 0 Bortezomib- Bortezomib- Total naive exposed (n=110) (n=63) (n=47) 2

  13. Slide 13: Best Response by Patient Characteristics

    Best Response by Patient Characteristics Bulky Disease (2 10 cm ) Refractory Yes No Prior high intensity therapy

  14. Slide 14: Best Response (Longer Follow Up)

    Best Response (Longer Follow Up on Initial 51 Patients Presented at ASH 2011) ASH 2011 (median 3.7 months) ASH 2012 (median 14.7 months) =CR uPR =CR UPR 100 100 = = 71% 9 ri 71% sy 60% an 1% 75% = = £60 260 & & 3 40 S40 z = 8 8 G 20 Pel 40% 38% & 2 16% 15% 0 Bortezomib- Bortezomib- Total Bortezomib-

  15. Slide 15: Phenomenon of Incremental Response

    (Phenomenon of Incremental Response) Bortezomib — naive Bortezomib-exposed Total (n=63) (n=47) (n=110) N 37 34 68 pana anne aaa Median (months) 19 18 19 Range (months) 148.4 15-91 149.1 Time to OR EREEEenaes) N B " 24 mien 58 nee Range (months) 1.7-16.4 1.7-11.0 1.7-16.4

  16. Slide 16: Phenomenon: Incremental Response

    Phenomenon: Incremental Response M.D. Anderson Sub-site Analysis Data cut on Sept 21, 2012

  17. Slide 17: Kaplan-Meier Progression-Free Survival and Duration of response

    Kaplan-Meier Progression-Free Survival and Duration of response PFS DOR 10: 4 a PA 2 2 du 3s 3 i i pe gu Responder i a 7 All Treated yl ee ; Tr To) 8 @ @ 8 8 > 3 8 $8 3 Worth in study Neate insudy {All Treated Population iit {All Responded Population 75 Median PFS (C1 95%) months 13.9 (664, NR) Medi

  18. Slide 18: Response after Cycles of Ibrutinib

    Response after 2 Cycles of Ibrutinib Patient #15: on 4/28/11 subcarinal LAD: 83x 54mm 7/15/11 subcarinal LAD: 21 x 13 mm

  19. Slide 19: PCYC-1104-CA: Conclusions

    PCYC-1104-CA: Conclusions Ibrutinib demonstrated in this study: — unprecedented single agent overall response rate in relapsed or refractory MCL — high CR rate Responses have been durable. + median duration of response not reached + median PFS of 13.9 months Response improved with longer follow-up w

  20. Slide 20: Acknowledgements

    Acknowledgements - All the patients and their families who participated in this trial * Investigators and clinical research staff from all participating centers: — John Radford, MD, Christie Hospital; Jacqueline Barrientos, MD, CLL Research and Treatment Program; Martin Dreyling, MD Klinikum der Uni

  21. Slide 21: Back Up

  22. Slide 22: PFS Probability

    PFS Probability 10 os 06 4 o24 00 Responder B-Naive B-Exposed 2 6 8 Median (988 CT) of 863 mA 16.6 (6.3, HR) PRS nontho}

  23. Slide 23: Median Absolute Lymphocyte Count by Cycle

    Median Absolute Lymphocyte Count (ALC) by Cycle a —_—— Proportion of patients experienced lymphocytosis is 42%

  24. Slide 24: Time on Study by Best Response

    Time on Study by Best Response 2 4 6 8 m2 4 16 (20 Months Median time on study treatment for responders is 10.1 months for both groups * Denotes the discontinuation of study treatment.

Pharmacyclics — Technical Presentation (December 2012) on 6ix